Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- New Molecular Target-based Therapeutics for Lung Cancer Presented: AstraZeneca Seminar
October 29, 2001
- WORLD NEWS IN BRIEF
October 29, 2001
- Overseas Business Strategy of Domestic Firms Focused on:PMSRL Seminar
October 29, 2001
- Chugai Licenses in Polyglutamate Paclitaxel from CTI Technologies
October 29, 2001
- Meiji Seika to Codevelop Antibiotics with Kosan Biosciences in US
October 29, 2001
- Kowa, Novartis to Comarket Hypadil Kowa Ophthalmic Solution
October 29, 2001
- 60th Annual Meeting of the Japanese Cancer Association
October 29, 2001
- Companies' Interest in Pharmacoeconomics Data Has Declined
October 29, 2001
- Administration of Statins to the Elderly Recommended: Results of PATE Study
October 29, 2001
- Taisho Tanabe Pharma Group to Focus on Ethical Drugs: Tanabe President
October 29, 2001
- Simvastatin Inhibits Coronary Arteriosclerosis: JUST Study
October 29, 2001
- BUSINESS NEWS IN BRIEF
October 29, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
October 29, 2001
- Drug Cost Ratio Down to 16.8% of Medical Cost for Outpatients in 1998
October 29, 2001
- Olympus Codevelops Ultrasound Surgical System with Intuitive Surgical of the US
October 29, 2001
- Glivec Recommended for Approval
October 29, 2001
- GEYMS Markets Fully-digital Ultrasound Diagnostic Equipment
October 29, 2001
- Dr Takemi, Lawmaker, Strongly Opposes Korosho, MOF Reform Plans
October 29, 2001
- Toshiba, NTT Com to Start ASP Services for Remote Imaging Diagnosis
October 29, 2001
- Korosho's NHI Price System Reform Is Full of Contradictions: Mr Yashiro of FPMAJ
October 29, 2001
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…